[{"id":"2cc142f0-936b-4d7c-a88d-8efcc58b34ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01606579","created_at":"2021-01-18T06:52:25.296Z","updated_at":"2024-07-02T16:37:18.780Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies","source_id_and_acronym":"NCT01606579","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 12/30/2016","primary_completion_date":" 12/30/2016","study_txt":" Completion: 12/30/2016","study_completion_date":" 12/30/2016","last_update_posted":"2017-08-17"},{"id":"df9ef5ca-d318-4e93-9501-779e49ce9ce1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01764477","created_at":"2021-01-18T07:45:28.718Z","updated_at":"2024-07-02T16:37:18.793Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT01764477","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" BIRC5 • MMP7","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5 • MMP7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-08-17"},{"id":"5a7c5489-b239-47d8-a356-42d94714ee1a","acronym":"PRIMIER","url":"https://clinicaltrials.gov/study/NCT02413853","created_at":"2021-01-18T11:31:51.660Z","updated_at":"2024-07-02T16:37:23.393Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02413853 - PRIMIER","lead_sponsor":"University of Southern California","biomarkers":" BRAF • BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BRAF • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-04-17"}]